-
Leading the Frontier, Shaping the Future | The Inaugural CSH–IACH Joint Symposium on “From Classics to Innovation: Advances in CAR-T Therapy” Successfully Concluded
The diagnosis and treatment of hematologic diseases remain a global challenge. In recent years, with the rapid emergence of innovative therapies such as chimeric antigen receptor T-cell (CAR-T) therapy and the deepening understanding of hematologic disorders, the field has entered a new era.
-
AACR 2026 | Qilu Pharmaceutical Showcases 12 Innovative Programs on the Global Stage: A Comprehensive Overview of ADCs, TCEs, Small-Molecule Inhibitors, and a Precision Oncology Portfolio
At the recently concluded 2026 Annual Meeting of the American Association for Cancer Research (AACR), Qilu Pharmaceutical presented 12 innovative oncology programs, including one oral presentation and eleven poster presentations. These studies span a wide range of tumor types, including gynecologic cancers, breast cancer, esophageal cancer, lung cancer, head and neck cancers, colorectal cancer, prostate…
-
CSCO Guidelines Conference 2026 | Professor Jun Zhu: Redefining the Future of Lymphoma Care—Guideline Updates Shaping a “China Solution”
To advance clinical oncology in China, enhance physicians’ diagnostic and research capabilities, and further promote the development and implementation of CSCO guidelines, the Chinese Society of Clinical Oncology (CSCO), together with the Beijing CSCO Clinical Oncology Research Foundation, co-hosted the 2026 CSCO Guidelines Conference in Harbin from April 24 to 25.
-
CSCO Guidelines Conference 2026 | Professor Jun Ma: Illuminating Standardized Care Through Guidelines—Driving High-Quality Development of Oncology Practice in China
To advance clinical oncology in China, enhance physicians’ diagnostic and research capabilities, and further promote the development and implementation of CSCO guidelines, the Chinese Society of Clinical Oncology (CSCO), together with the Beijing CSCO Clinical Oncology Research Foundation, co-hosted the 2026 CSCO Guidelines Conference in Harbin from April 24 to 25.
-
EBMT Global Perspective | Professor Donal McLornan: Defining Remission Criteria and Optimizing Novel Combination Strategies for Bone Marrow Transplantation in MDS/MPN Overlap Syndromes
Myelodysplastic/myeloproliferative neoplasm (MDS/MPN) overlap syndromes are rare hematologic malignancies characterized by marked clinical heterogeneity and significant diagnostic and therapeutic challenges. Allogeneic hematopoietic stem cell transplantation remains a key treatment option; however, the lack of standardized criteria for assessing post-transplant remission and relapse represents a major unmet clinical need.
-
EBMT President Professor Ibrahim Yakoub-Agha: A Global Vision for the Future of Therapy—Strengthening Collaboration, Empowering Data, and Standardizing Cellular Therapies
As a leading global academic organization in transplantation and cellular therapy, the European Society for Blood and Marrow Transplantation (EBMT) has long been committed to advancing clinical research, optimizing patient management, and fostering international collaboration. In the era of rapid progress in cell and gene therapies, EBMT is entering a new phase of opportunity.
-
EBMT Global Perspective | Professor Francesca Ferrua: Breakthroughs in Autologous Hematopoietic Stem Cell Gene Therapy for WAS—From Concept to Clinical Practice
Wiskott–Aldrich syndrome (WAS) is a rare X-linked primary immunodeficiency characterized by thrombocytopenia, eczema, and recurrent infections, posing a serious threat to affected children. While allogeneic hematopoietic stem cell transplantation (HSCT) can be curative, it is limited by donor availability, the risk of graft-versus-host disease (GVHD), and conditioning-related toxicity.
-
EBMT Global Perspective | Professor Annalisa Ruggeri: Cord Blood Transplantation—From Established Platform to Frontier Therapeutic Modality
Cord blood transplantation (CBT), an important modality within hematopoietic stem cell transplantation, has faced increasing competition in recent years from alternative donor strategies such as haploidentical transplantation. As a result, the field is undergoing a period of reassessment and transformation. Nevertheless, CBT retains irreplaceable value in selected patient populations, while its potential applications in cell…
Connecting Medical Expertise through Media